Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

ogram for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of NKTR-102 for breast cancer patients, preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the Phase 2 data for NKTR-102 in breast cancer in this press release remain subject to audit and confirmation procedures, and the final results may change materially and adversely after such procedures are completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in metastatic breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete and final results for this study may diff
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Chronic Lymphocytic Leukemia ... condition characterized by increased production of lymphocytes. It has ... then it can spread to other parts of the ... because of the slow buildup of the cancerous cells. ... to the spleen, liver, and lymph nodes. The course ...
(Date:9/2/2015)... 2, 2015   Physicians Rx Pharmacy ("PRxP") ... joined the organization as President and Chief Executive Officer.  ... President and Chief Executive Officer for Soleo Health Specialty ... of Physicians Rx Pharmacy, be responsible for leading the ... extremely pleased to bring Gaston on as the President ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
... 6, 2007 - Neurologix, Inc.,(OTCBB:NRGX), a biotechnology company ... the brain and central nervous system,announced today that ... Unterberg Towbin Emerging Growth Conference on Tuesday July,10, ... Oriental Hotel in New York., President and Chief ...
... 05, 2007 /PRNewswire/ -- Alfacell,Corporation today announced ... financial officer and corporate secretary, will,present an ... 8 a.m. EDT on Thursday, July 12, ... Opportunities Conference in New York. , The ...
Cached Medicine Technology:Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference 2
(Date:9/3/2015)... , ... September 03, 2015 , ... A scar is an unavoidable result of incision ... example of the body's ability to heal itself. The appearance of a scar is dependent ... individual's age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their own ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... will be participating at the highly anticipated Mississippi Gulf Babypalooza on September 19, ... from all over, from Gulfport, Biloxi, and beyond. We will be discussing setting ...
(Date:9/3/2015)... ... ... 220,800 new cases of prostate cancer are reported each year, along with 27,540 deaths attributed ... their lifetime. While only one man in 10,000 will typically get prostate cancer under age ... the American Cancer Society. , Prostate cancer is the second leading ...
(Date:9/3/2015)... ... ... Doctor Kayode Sotonwa can be counted on time and time ... medicine keeps patients happy and healthy, something that is important to everyone. In fact, ... even more so in the fall, when holiday eating and seasonal illnesses are potential ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah Binder, MA, MGA, president ... leaders in healthcare, will offer the keynote address at the upcoming meeting of ... in Palm Harbor, Florida, at the Innisbrook Resort and Golf Club. For an ...
Breaking Medicine News(10 mins):Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3
... health care, doctors are often pressed for time during ... a tool that allows doctors to view electronic information ... single computer screen. A new study shows that this ... enhances patient care. The diabetes dashboard provides information ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, Nov. ... into her day-to-day meals didn,t stem from any aversion to them. ... that," said Stewart, 67, a Baltimore resident who said her love ... meal -- we were brought up that way -- so we ...
... press release is available in French . ... noses, sore throats and clammy skin are as seasonal as ... they insecure about their jobs? A new study ... Health Psychology , has found that presenteeism, i.e. attending work ...
... The New Jersey Health Information Technology Extension Center (NJ-HITEC) ... care providers member milestone in support of the healthcare ... Each member doctor has signed an agreement pledging ... of EHRs; to earn the federal incentive funds pursuant ...
... Nov. 17 (HealthDay News) -- For the first time in more ... new U.S. government report shows. Although the drop reported by ... percent in 2009 to 32.8 percent in 2010, experts say it ... leveled off. "But with only one data point, we have ...
... tumor cells circulating in the blood might be possible ... branched synthetic polymers, which could efficiently sift and capture ... University of Illinois at Chicago. Dendrimers have been ... delivery vehicle, but in the new study they were ...
Cached Medicine News:Health News:MU researchers develop tool that saves time, eliminates mistakes in diabetes care 2Health News:Not Everyone Shuns Fruits and Veggies 2Health News:Presenteeism: A new word for working when sick 2Health News:NJ docs beat fed deadline: Signing up in droves for electronic health records 2Health News:C-Section Rate Drops for First Time in a Decade in U.S. 2Health News:C-Section Rate Drops for First Time in a Decade in U.S. 3Health News:Molecules on branched-polymer surfaces can capture rare tumor cells in blood 2
... Compact desktop analyzer for fast point-of-care ... syndrome, deep vein thrombosis and/or pulmonary embolism. ... rooms. , ,When every minute counts, ... determination of troponin T, myoglobin, and D-Dimer ...
... Collection Tubes are 100% plastic capillary blood ... of applications, the Capillary Collection Tubes are ... and a micro tube.,The capillary tube uses ... the micro tube thereby eliminating the tendency ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
... SAFE-T-FILL Capillary Blood Collection Tubes are 100% ... a wide range of applications, the Capillary ... tube, attached cap and a micro tube.,The ... the blood into the micro tube thereby ...
Medicine Products: